Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Cash & Current Investments (2018 - 2025)

10x Genomics' Cash & Current Investments history spans 8 years, with the latest figure at $523.4 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 33.05% year-over-year to $523.4 million; the TTM value through Dec 2025 reached $523.4 million, up 33.05%, while the annual FY2025 figure was $523.4 million, 33.05% up from the prior year.
  • Cash & Current Investments for Q4 2025 was $523.4 million at 10x Genomics, up from $482.1 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $640.1 million in Q2 2021 and bottomed at $222.4 million in Q4 2022.
  • The 5-year median for Cash & Current Investments is $395.8 million (2024), against an average of $425.9 million.
  • The largest annual shift saw Cash & Current Investments plummeted 62.14% in 2022 before it skyrocketed 74.79% in 2023.
  • A 5-year view of Cash & Current Investments shows it stood at $587.4 million in 2021, then tumbled by 62.14% to $222.4 million in 2022, then surged by 74.79% to $388.7 million in 2023, then increased by 1.21% to $393.4 million in 2024, then skyrocketed by 33.05% to $523.4 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Cash & Current Investments are $523.4 million (Q4 2025), $482.1 million (Q3 2025), and $447.3 million (Q2 2025).